MA28550B1 - Composes et procedes permettant de traiter la dyslipidemie - Google Patents
Composes et procedes permettant de traiter la dyslipidemieInfo
- Publication number
- MA28550B1 MA28550B1 MA29410A MA29410A MA28550B1 MA 28550 B1 MA28550 B1 MA 28550B1 MA 29410 A MA29410 A MA 29410A MA 29410 A MA29410 A MA 29410A MA 28550 B1 MA28550 B1 MA 28550B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- compounds
- treating dyslipidemia
- dyslipidemia
- treating
- Prior art date
Links
- 208000032928 Dyslipidaemia Diseases 0.000 title abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55713404P | 2004-03-26 | 2004-03-26 | |
| US62116204P | 2004-10-22 | 2004-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28550B1 true MA28550B1 (fr) | 2007-04-03 |
Family
ID=34963426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29410A MA28550B1 (fr) | 2004-03-26 | 2006-10-23 | Composes et procedes permettant de traiter la dyslipidemie |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20070208003A1 (fr) |
| EP (2) | EP1732933B1 (fr) |
| JP (1) | JP2007530550A (fr) |
| KR (1) | KR20070007112A (fr) |
| AT (2) | ATE402180T1 (fr) |
| AU (1) | AU2005230915A1 (fr) |
| BR (1) | BRPI0508966A (fr) |
| CA (1) | CA2557010A1 (fr) |
| CY (1) | CY1110398T1 (fr) |
| DE (2) | DE602005014955D1 (fr) |
| DK (1) | DK1732933T3 (fr) |
| EA (1) | EA200601785A1 (fr) |
| EC (1) | ECSP066886A (fr) |
| ES (2) | ES2308477T3 (fr) |
| IL (1) | IL177962A0 (fr) |
| MA (1) | MA28550B1 (fr) |
| NO (1) | NO20064763L (fr) |
| PL (1) | PL1732933T3 (fr) |
| PT (1) | PT1732933E (fr) |
| SI (1) | SI1732933T1 (fr) |
| WO (2) | WO2005097805A1 (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7749992B2 (en) * | 2003-10-08 | 2010-07-06 | Eli Lilly And Company | Compounds and methods for treating dislipidemia |
| ATE402180T1 (de) * | 2004-03-26 | 2008-08-15 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| TWI345568B (en) | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
| KR20070041452A (ko) | 2004-06-24 | 2007-04-18 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
| US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| CN103102303B (zh) | 2004-12-31 | 2015-10-28 | 雷迪博士实验室有限公司 | 作为cetp抑制剂的苄胺衍生物 |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
| AR069165A1 (es) | 2007-11-05 | 2010-01-06 | Novartis Ag | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia |
| WO2009071509A1 (fr) | 2007-12-03 | 2009-06-11 | Novartis Ag | Dérivés de 4-benzylaminopyrrolidine 1,2-disubstituée comme inhibiteurs de cetp utiles pour le traitement de maladies telles que l'hyperlipidémie ou l'artériosclérose |
| JP2011506441A (ja) * | 2007-12-12 | 2011-03-03 | アムジエン・インコーポレーテツド | グリシン輸送体−１阻害薬 |
| JP5586585B2 (ja) * | 2009-03-27 | 2014-09-10 | 興和株式会社 | 縮合ピペリジン化合物及びこれを含有する医薬 |
| CN102803217B (zh) | 2009-05-15 | 2015-06-17 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基吡啶 |
| EA201101621A1 (ru) | 2009-05-15 | 2012-05-30 | Новартис Аг | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы |
| EP2435402B1 (fr) | 2009-05-28 | 2016-04-13 | Novartis AG | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| AR077208A1 (es) | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
| JP5654608B2 (ja) | 2009-11-17 | 2015-01-14 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| EP2507234B1 (fr) | 2009-11-30 | 2014-03-12 | Novartis AG | Dérivés d'imidazole en tant qu'inhibiteurs de l'aldostérone synthase |
| WO2011106545A1 (fr) * | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Polyimidazoles pour emploi en tant qu'agents séquestrants d'acide biliaire |
| MX336872B (es) | 2010-05-06 | 2016-02-04 | Medimmune Llc | Suministro de ester de colesterol a tejidos esteroidogenicos. |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| CN103648495A (zh) | 2011-07-08 | 2014-03-19 | 诺华股份有限公司 | 在高甘油三酯对象中治疗动脉粥样硬化的方法 |
| JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物 |
| CN103958511A (zh) | 2011-09-27 | 2014-07-30 | 雷迪博士实验室有限公司 | 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物 |
| JO3210B1 (ar) | 2011-10-28 | 2018-03-08 | Merck Sharp & Dohme | مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة |
| US20140303198A1 (en) | 2011-11-29 | 2014-10-09 | Kowa Company, Ltd. | Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| EA028583B1 (ru) | 2013-02-14 | 2017-12-29 | Новартис Аг | Замещенные бис-фенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза) |
| KR20160031551A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 심부전의 치료를 위한 시클릭 폴리펩티드 |
| HK1218252A1 (zh) | 2013-07-25 | 2017-02-10 | Novartis Ag | 合成apelin多肽之生物结合物 |
| CR20170338A (es) | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de ácidos grasos y apelina sintética con mayor vida media |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| US20240391941A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1515540A (en) | 1975-12-16 | 1978-06-28 | Labaz | 4-amino-trans-decahydroquinoline derivatives |
| DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| WO1998035967A2 (fr) * | 1997-02-18 | 1998-08-20 | Neurocrine Biosciences, Inc. | Antagonistes de recepteurs du crf et procedes associes |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法 |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| EP1466904A4 (fr) * | 2001-12-28 | 2005-12-14 | Takeda Pharmaceutical | Compose biaryle et son utilisation |
| IL162870A0 (en) | 2002-02-01 | 2005-11-20 | Pfizer Prod Inc | Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor |
| JP2003321472A (ja) * | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤 |
| EP1829858A3 (fr) | 2002-08-30 | 2007-10-03 | Japan Tobacco, Inc. | Composés de dibenzylamine et leur utilisation pharmaceutique |
| KR20050055747A (ko) * | 2002-10-04 | 2005-06-13 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료용의 ｐｇｄ2 수용체 길항제 |
| US7749992B2 (en) * | 2003-10-08 | 2010-07-06 | Eli Lilly And Company | Compounds and methods for treating dislipidemia |
| ATE402180T1 (de) | 2004-03-26 | 2008-08-15 | Lilly Co Eli | Verbindungen zur behandlung von dyslipidemie |
| TWI345568B (en) * | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
| KR20070041452A (ko) * | 2004-06-24 | 2007-04-18 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
-
2005
- 2005-03-17 AT AT05732643T patent/ATE402180T1/de not_active IP Right Cessation
- 2005-03-17 ES ES05732643T patent/ES2308477T3/es not_active Expired - Lifetime
- 2005-03-17 EA EA200601785A patent/EA200601785A1/ru unknown
- 2005-03-17 US US10/598,686 patent/US20070208003A1/en not_active Abandoned
- 2005-03-17 CA CA002557010A patent/CA2557010A1/fr not_active Abandoned
- 2005-03-17 AT AT05725968T patent/ATE433984T1/de not_active IP Right Cessation
- 2005-03-17 DE DE602005014955T patent/DE602005014955D1/de not_active Expired - Fee Related
- 2005-03-17 US US10/598,473 patent/US7470705B2/en not_active Expired - Fee Related
- 2005-03-17 EP EP05732643A patent/EP1732933B1/fr not_active Expired - Lifetime
- 2005-03-17 DK DK05732643T patent/DK1732933T3/da active
- 2005-03-17 BR BRPI0508966-2A patent/BRPI0508966A/pt not_active Application Discontinuation
- 2005-03-17 EP EP05725968A patent/EP1735320B1/fr not_active Expired - Lifetime
- 2005-03-17 DE DE602005008416T patent/DE602005008416D1/de not_active Expired - Fee Related
- 2005-03-17 PT PT05732643T patent/PT1732933E/pt unknown
- 2005-03-17 SI SI200530352T patent/SI1732933T1/sl unknown
- 2005-03-17 AU AU2005230915A patent/AU2005230915A1/en not_active Abandoned
- 2005-03-17 JP JP2007505054A patent/JP2007530550A/ja active Pending
- 2005-03-17 WO PCT/US2005/009294 patent/WO2005097805A1/fr not_active Ceased
- 2005-03-17 KR KR1020067019800A patent/KR20070007112A/ko not_active Ceased
- 2005-03-17 ES ES05725968T patent/ES2326326T3/es not_active Expired - Lifetime
- 2005-03-17 WO PCT/US2005/009301 patent/WO2005097806A1/fr not_active Ceased
- 2005-03-17 PL PL05732643T patent/PL1732933T3/pl unknown
-
2006
- 2006-09-07 IL IL177962A patent/IL177962A0/en unknown
- 2006-09-26 EC EC2006006886A patent/ECSP066886A/es unknown
- 2006-10-20 NO NO20064763A patent/NO20064763L/no not_active Application Discontinuation
- 2006-10-23 MA MA29410A patent/MA28550B1/fr unknown
-
2008
- 2008-09-24 CY CY20081101030T patent/CY1110398T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070173526A1 (en) | 2007-07-26 |
| CA2557010A1 (fr) | 2005-10-20 |
| BRPI0508966A (pt) | 2007-08-21 |
| EP1732933A1 (fr) | 2006-12-20 |
| ES2308477T3 (es) | 2008-12-01 |
| CY1110398T1 (el) | 2015-04-29 |
| EP1735320A1 (fr) | 2006-12-27 |
| ES2326326T3 (es) | 2009-10-07 |
| EP1732933B1 (fr) | 2008-07-23 |
| KR20070007112A (ko) | 2007-01-12 |
| DE602005008416D1 (de) | 2008-09-04 |
| PL1732933T3 (pl) | 2008-12-31 |
| ATE402180T1 (de) | 2008-08-15 |
| ECSP066886A (es) | 2006-11-24 |
| US20070208003A1 (en) | 2007-09-06 |
| IL177962A0 (en) | 2006-12-31 |
| EA200601785A1 (ru) | 2007-02-27 |
| JP2007530550A (ja) | 2007-11-01 |
| DK1732933T3 (da) | 2008-10-27 |
| AU2005230915A1 (en) | 2005-10-20 |
| SI1732933T1 (sl) | 2008-10-31 |
| ATE433984T1 (de) | 2009-07-15 |
| NO20064763L (no) | 2006-11-22 |
| PT1732933E (pt) | 2008-10-20 |
| EP1735320B1 (fr) | 2009-06-17 |
| WO2005097805A1 (fr) | 2005-10-20 |
| DE602005014955D1 (de) | 2009-07-30 |
| WO2005097806A1 (fr) | 2005-10-20 |
| US7470705B2 (en) | 2008-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA28550B1 (fr) | Composes et procedes permettant de traiter la dyslipidemie | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
| NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
| SE0302811D0 (sv) | Novel compounds | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| TW200617009A (en) | Organic compounds | |
| TW200626579A (en) | Inhibitors of the interaction between MDM2 and p53 | |
| ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
| ATE547415T1 (de) | Inhibitoren der wechselwirkung zwischen mdm2 und p53 | |
| TW200640859A (en) | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | |
| ATE422198T1 (de) | Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten | |
| JO2704B1 (en) | Interference inhibition factors between MD2 and B53 | |
| SE0303541D0 (sv) | New compounds | |
| TW200510427A (en) | Novel fused heterocycles and uses thereof | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| TW200616977A (en) | Enantiomers of selected fused heterocyclics and uses thereof | |
| NO20064351L (no) | Caspaseinhibitorer og anvendelser derav | |
| MA28268A1 (fr) | Composes et techniques de traitement de la dyslipidemie | |
| SE0303090D0 (sv) | Novel compounds | |
| TW200740781A (en) | Novel compounds | |
| NO20063293L (no) | Farmasoytiske forbindelser | |
| BRPI0615141A2 (pt) | inibidores pentacìclicos de quinase | |
| TW200621260A (en) | Selected fused heterocyclics and uses thereof |